Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Randomized, Controlled Phase III Trial Evaluating the Efficacy and Safety of EndoTAG®-1 in Combination With Paclitaxel and Gemcitabine Compared With Paclitaxel and Gemcitabine as First-line Therapy in Patients With Visceral Metastatic Triple-negative Breast Cancer

NCT03002103 is registered in ClinicalTrials.gov with SynCore Biotechnology Co., Ltd. as lead sponsor.

NCT NCT03002103
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03002103 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Randomized, Controlled Phase III Trial Evaluating the Efficacy and Safety of EndoTAG®-1 in Combination With Paclitaxel and Gemcitabine Compared With Paclitaxel and Gemcitabine as First-line Therapy in Patients With Visceral Metastatic Triple-negative Breast Cancer
Lead sponsor
SynCore Biotechnology Co., Ltd.
Phase
Phase 3
Overall status
Suspended
Start date
November 23, 2016
Completion date
June 30, 2027
Enrollment
420 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

triple-negative breast cancer